Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsInterest & Investment IncomeNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Roivant Sciences (ROIV) Operating Expenses (2020 - 2025)

Historic Operating Expenses for Roivant Sciences (ROIV) over the last 6 years, with Q4 2025 value amounting to $341.2 million.

  • Roivant Sciences' Operating Expenses rose 2037.87% to $341.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $936.0 million, marking a year-over-year increase of 1009.75%. This contributed to the annual value of $1.1 billion for FY2025, which is 2925.52% up from last year.
  • Latest data reveals that Roivant Sciences reported Operating Expenses of $341.2 million as of Q4 2025, which was up 2037.87% from $307.8 million recorded in Q3 2025.
  • Over the past 5 years, Roivant Sciences' Operating Expenses peaked at $698.4 million during Q3 2021, and registered a low of $162.1 million during Q2 2021.
  • In the last 5 years, Roivant Sciences' Operating Expenses had a median value of $287.1 million in 2025 and averaged $309.6 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first surged by 34241.63% in 2021, then plummeted by 5800.51% in 2022.
  • Over the past 5 years, Roivant Sciences' Operating Expenses (Quarter) stood at $270.4 million in 2021, then soared by 46.15% to $395.1 million in 2022, then tumbled by 40.14% to $236.5 million in 2023, then rose by 19.82% to $283.4 million in 2024, then increased by 20.38% to $341.2 million in 2025.
  • Its Operating Expenses was $341.2 million in Q4 2025, compared to $307.8 million in Q3 2025 and $287.1 million in Q2 2025.